Prelude Therapeutics Inc (PRLD)
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Prelude Therapeutics Incorporated
NASDAQ:PRLDHealthcare · Biotechnology
-5.37%$3.88
AH$3.85-0.77%vs close
Mkt Cap$309.64M
Float38.72M
O/S79.8M
Vol
$ Vol
RVOL
Inst Own62.1%
SI13.2%
Earnings
Dilution
Financials Summary
Revenue$12.14M
Net Income-$99.5M
Total Assets$141.31M
Free Cash Flow-$56.37M
Debt & Equity
Debt 21%
Equity 79%
Total Debt$17.79M
Total Equity$68.64M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in PRLD's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$141.31M
Liabilities$72.68M
Accounts Receivable$0
Accounts Payable$3.98M
Inventory$0
PP&E (Net)$32.28M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Revenue | $12.14M | $7M | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | 73.4% | - | - | - | - | - | - | - |
| Cost of Revenue | $1.71M | $0 | $0 | $0 | $0 | $0 | $0 | $149K |
| Gross Profit | $10.43M | $7M | $0 | $0 | $0 | $0 | $0 | -$149K |
| Gross Margin | 85.9% | 100.0% | - | - | - | - | - | - |
| Research and Development | $94.3M | $118M | $103.39M | $92.89M | $86.78M | $48.18M | $24.28M | $12.62M |
| Selling, General, and Administrative | $22.41M | $28.72M | $28.88M | $30.65M | $26.96M | $10.59M | $3.83M | $2.35M |
| Other | -$1.71M | $0 | -$1 | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $115M | $146.71M | $132.28M | $123.54M | $113.73M | $58.76M | $28.11M | $14.97M |
| Operating Income (EBIT) | -$104.57M | -$139.71M | -$132.28M | -$123.54M | -$113.73M | -$58.76M | -$28.11M | -$14.97M |
| Operating Margin | -861.3% | -1995.9% | - | - | - | - | - | - |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Interest Income | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Income (Expense) | $5.07M | $12.54M | $10.44M | $8.1M | $2.04M | $1.83M | $539K | $295K |
| Income Before Tax (EBT) | -$99.5M | -$127.17M | -$121.83M | -$115.44M | -$111.69M | -$56.93M | -$27.57M | -$14.68M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$99.5M | -$127.17M | -$121.83M | -$115.44M | -$111.69M | -$56.93M | -$27.57M | -$14.68M |
| Net Income Margin | -819.6% | -1816.8% | - | - | - | - | - | - |
| Supplementary Data | ||||||||
| EPS | -1.29 | -1.68 | -2.02 | -2.27 | -2.33 | -1.30 | -0.85 | -9.31 |
| Diluted EPS | -1.29 | -1.68 | -2.02 | -2.27 | -2.33 | -1.30 | -0.85 | -9.31 |
| Weighted Average OS | 76.96M | 75.81M | 60.36M | 47.37M | 47.60M | 43.71M | 32.40M | 1.58M |
| EBITDA | -$97.79M | -$125.4M | -$120.66M | -$114.11M | -$110.78M | -$58.22M | -$27.73M | -$14.83M |
| EBITDA Margin | -805.5% | -1791.4% | - | - | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Assets | ||||||||
| Current Assets | ||||||||
| Cash and Cash Equivalents | $35.26M | $12.47M | $25.29M | $30.61M | $31.83M | $218.31M | $18.88M | $15.6M |
| Short-Term Investments | $67.96M | $121.14M | $207.64M | $171.12M | $259.4M | $0 | $0 | $0 |
| Cash and Short-Term Investments | $103.21M | $133.61M | $232.94M | $201.73M | $291.23M | $218.31M | $18.88M | $15.6M |
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $2.48M | $2.28M | $2.65M | $2.65M | $0 | $2.5M | $0 | $0 |
| Total Current Assets | $105.69M | $135.9M | $235.59M | $204.38M | $295.12M | $220.81M | $20.22M | $15.6M |
| Long-Term Assets | ||||||||
| Property, Plant & Equipment Net | $32.28M | $35.47M | $37.74M | $6.7M | $5.64M | $2.48M | $1.65M | $811K |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $3.35M | $4.15M | $4.34M | $9.42M | $4.35M | $301K | $0 | $0 |
| Total Long-Term Assets | $35.62M | $39.62M | $42.08M | $16.12M | $9.98M | $2.78M | $1.65M | $811K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $141.31M | $175.51M | $277.67M | $220.5M | $305.1M | $223.59M | $21.87M | $16.41M |
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts Payable | $3.98M | $7.73M | $4.58M | $6.78M | $7.84M | $3.92M | $1.97M | $1.36M |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $33.73M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $5.39M | $9.79M | $6.61M | $6.21M | $5.01M | $420K | $1.63M | $0 |
| Total Current Liabilities | $52.99M | $25.64M | $21.83M | $21.7M | $19.2M | $11.38M | $4.83M | $2.45M |
| Long-Term Liabilities | ||||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $1.8M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $2.84M | $3.09M | $3.34M | $3.36M | $0 | $32K | $66.45M | $36.65M |
| Total Long-Term Liabilities | $19.68M | $18.41M | $18.75M | $3.36M | $0 | $32K | $66.45M | $36.65M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $72.68M | $44.06M | $40.58M | $25.06M | $19.2M | $11.41M | $71.28M | $39.1M |
| Stockholders' Equity | ||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $223.59M | $0 | $36.59M |
| Common Stock | $5K | $5K | $5K | $5K | $5K | $4K | $0 | $0 |
| Retained Earnings | -$683.06M | -$583.56M | -$456.39M | -$334.56M | -$219.12M | -$107.43M | -$50.5M | -$22.93M |
| Comprehensive Income & Other | $8K | $35K | $223K | -$1.69M | -$711K | -$223.59M | $0 | -$191K |
| Other Stockholders' Equity | $751.69M | $715.02M | $693.48M | $529.99M | $505.01M | $319.61M | $1.08M | $234K |
| Total Equity | $68.64M | $131.46M | $237.09M | $195.44M | $285.9M | $212.18M | -$49.41M | -$22.69M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $141.31M | $175.51M | $277.67M | $220.5M | $305.1M | $223.59M | $21.87M | $16.41M |
| Supplementary Data | ||||||||
| Total Debt | $17.79M | $18.02M | $16.89M | $1.83M | $1.74M | $0 | $258K | $0 |
| Net Debt | -$17.47M | $5.55M | -$8.4M | -$28.77M | -$30.09M | -$218.31M | -$18.62M | -$15.6M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Operating Activities | ||||||||
| Net Income | -$99.5M | -$127.17M | -$121.83M | -$115.44M | -$111.69M | -$56.93M | -$27.57M | -$14.68M |
| Depreciation & Amortization | $1.71M | $1.77M | $1.17M | $1.32M | $915K | $542K | $382K | $149K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $11.91M | $21.34M | $25.62M | $25.14M | $20.93M | $5.58M | $846K | $180K |
| Changes in Working Capital: | ||||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | -$3.92M | $3.31M | -$2.27M | -$347K | $3.9M | $1.16M | $546K | $721K |
| Other Working Capital | $32.33M | $911K | -$8.21M | $1.28M | -$278K | $3.46M | $121K | $661K |
| Total Working Capital Change | $28.41M | $4.22M | -$10.48M | $932K | $3.63M | $4.62M | $667K | $1.38M |
| Other Non-Cash Items | $1.16M | -$3.05M | -$1.54M | $4.31M | $2.69M | $11K | $10K | $15K |
| Net Cash from Operating | -$56.3M | -$102.89M | -$107.06M | -$83.73M | -$83.53M | -$46.18M | -$25.66M | -$12.95M |
| Investing Activities | ||||||||
| Capital Expenditures | -$67K | -$764K | -$3.51M | -$3.02M | -$2.32M | -$621K | -$780K | -$529K |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$100.87M | -$52.69M | -$221.63M | -$119.22M | -$261.48M | $0 | $0 | $0 |
| Sales of Investments | $154.39M | $143.65M | $190.5M | $203.93M | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | $53.46M | $90.19M | -$34.65M | $81.69M | -$263.8M | -$621K | -$780K | -$529K |
| Financing Activities | ||||||||
| Debt Repaid | $208K | $395K | - | - | - | $258K | $124K | - |
| Common Stock Issuance | $25.04M | $439K | $136.41M | $815K | $161.42M | $166.63M | $0 | $17.94M |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$17K | -$164K | -$17K | $0 | $3.47M | $88K | $5K | $0 |
| Net Cash from Financing | $24.82M | -$120K | $136.4M | $815K | $164.9M | $246.23M | $29.73M | $17.94M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $21.97M | -$12.82M | -$5.31M | -$1.22M | -$182.44M | $199.43M | $3.28M | $4.45M |
| Supplementary Data | ||||||||
| Operating Cash Flow | -$56.3M | -$102.89M | -$107.06M | -$83.73M | -$83.53M | -$46.18M | -$25.66M | -$12.95M |
| Capital Expenditure | -$67K | -$764K | -$3.51M | -$3.02M | -$2.32M | -$621K | -$780K | -$529K |
| Free Cash Flow | -$56.37M | -$103.65M | -$110.58M | -$86.75M | -$85.85M | -$46.8M | -$26.45M | -$13.48M |
| Cash at Beginning | $16.52M | $29.34M | $34.65M | $35.87M | $218.31M | $18.88M | $15.6M | $11.14M |
| Cash at End | $38.49M | $16.52M | $29.34M | $34.65M | $35.87M | $218.31M | $18.88M | $15.6M |